These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, Xin B, Luettgen JM, Wong PC. J Thromb Thrombolysis; 2010 Jan; 29(1):70-80. PubMed ID: 19851712 [Abstract] [Full Text] [Related]
4. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Wong PC, Crain EJ, Watson CA, Xin B. J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242 [Abstract] [Full Text] [Related]
5. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. He K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ. Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):129-39. PubMed ID: 21461793 [Abstract] [Full Text] [Related]
6. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ. Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130 [Abstract] [Full Text] [Related]
8. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. J Thromb Haemost; 2008 May; 6(5):820-9. PubMed ID: 18315548 [Abstract] [Full Text] [Related]
9. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Wong PC, Jiang X. Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316 [Abstract] [Full Text] [Related]
10. [Apixaban: pharmacology and action profile]. Gassanov N, Caglayan E, Er F. Dtsch Med Wochenschr; 2012 Jan; 137(4):138-41. PubMed ID: 22259168 [Abstract] [Full Text] [Related]
14. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Hillarp A, Gustafsson KM, Faxälv L, Strandberg K, Baghaei F, Fagerberg Blixter I, Berndtsson M, Lindahl TL. J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851 [Abstract] [Full Text] [Related]
15. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Carreiro J, Ansell J. Expert Opin Investig Drugs; 2008 Dec; 17(12):1937-45. PubMed ID: 19012508 [Abstract] [Full Text] [Related]
18. Apixaban: a new player in the anticoagulant class. Agrawal R, Jain P, Dikshit SN. Curr Drug Targets; 2012 Jun; 13(6):863-75. PubMed ID: 22250655 [Abstract] [Full Text] [Related]
19. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Zhang D, Frost CE, He K, Rodrigues AD, Wang X, Wang L, Goosen TC, Humphreys WG. Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703 [Abstract] [Full Text] [Related]